Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease

被引:7
|
作者
Wang, Guoqiao [1 ,2 ]
Liu, Lei [1 ]
Li, Yan [2 ]
Aschenbrenner, Andrew J. [2 ]
Bateman, Randall J. [2 ]
Delmar, Paul [3 ]
Schneider, Lon S. [4 ]
Kennedy, Richard E. [5 ]
Cutter, Gary R. [6 ]
Xiong, Chengjie [1 ,2 ]
机构
[1] Washington Univ, Div Biostat, Sch Med, St Louis, MO 63110 USA
[2] Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Univ Southern Calif, Dept Psychiat & Behav Sci, Dept Neurol, Keck Sch Med, Los Angeles, CA 90007 USA
[5] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[6] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA
关键词
Alzheimer's disease; proportional constrained longitudinal data analysis model (PcLDA); MMRM; proportional MMRM (pMMRM); proportional treatment effect; SOLANEZUMAB; EFFICIENCY; MEMANTINE; DEMENTIA;
D O I
10.1002/trc2.12286
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Clinical trials for sporadic Alzheimer's disease generally use mixed models for repeated measures (MMRM) or, to a lesser degree, constrained longitudinal data analysis models (cLDA) as the analysis model with time since baseline as a categorical variable. Inferences using MMRM/cLDA focus on the between-group contrast at the pre-determined, end-of-study assessments, thus are less efficient (eg, less power). Methods The proportional cLDA (PcLDA) and proportional MMRM (pMMRM) with time as a categorical variable are proposed to use all the post-baseline data without the linearity assumption on disease progression. Results Compared with the traditional cLDA/MMRM models, PcLDA or pMMRM lead to greater gain in power (up to 20% to 30%) while maintaining type I error control. Discussion The PcLDA framework offers a variety of possibilities to model longitudinal data such as proportional MMRM (pMMRM) and two-part pMMRM which can model heterogeneous cohorts more efficiently and model co-primary endpoints simultaneously.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Analysis of longitudinal data in an Alzheimer's disease clinical trial
    Thomas, RG
    Berg, JD
    Sano, M
    Thal, L
    [J]. STATISTICS IN MEDICINE, 2000, 19 (11-12) : 1433 - 1440
  • [2] Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
    Wang, Hui-Fu
    Shen, Xue-Ning
    Li, Jie-Qiong
    Suckling, John
    Tan, Chen-Chen
    Wang, Yan-Jiang
    Feng, Lei
    Zhang, Can
    Tan, Lan
    Dong, Qiang
    Touchon, Jacques
    Gauthier, Serge
    Yu, Jin-Tai
    [J]. ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)
  • [3] Temporally Constrained Group Sparse Learning for Longitudinal Data Analysis in Alzheimer's Disease
    Jie, Biao
    Liu, Mingxia
    Liu, Jun
    Zhang, Daoqiang
    Shen, Dinggang
    [J]. IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 2017, 64 (01) : 238 - 249
  • [4] Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials
    Donohue, Michael C.
    Moghadam, Setareh H.
    Roe, Allyson D.
    Sun, Chung-Kai
    Edland, Steven D.
    Thomas, Ronald G.
    Petersen, Ronald C.
    Sano, Mary
    Galasko, Douglas
    Aisen, Paul S.
    Rissman, Robert A.
    [J]. ALZHEIMERS & DEMENTIA, 2015, 11 (09) : 1069 - 1079
  • [5] Clinical Data Interchange Standards in Clinical Trials on Alzheimer?s Disease
    Na, Riyoung
    Bin Bae, Jong
    Jung, Sue Hyun
    Kim, Ki Woong
    [J]. PSYCHIATRY INVESTIGATION, 2022, 19 (10) : 814 - 823
  • [6] Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models
    Oxtoby, Neil P.
    Shand, Cameron
    Cash, David M.
    Alexander, Daniel C.
    Barkhof, Frederik
    [J]. FRONTIERS IN ARTIFICIAL INTELLIGENCE, 2022, 5
  • [7] Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease
    Han, Yangtong
    Jia, Jianping
    Jia, Xiang-Fei
    Qin, Wei
    Wang, Suying
    [J]. NEUROSCIENCE LETTERS, 2012, 516 (02) : 232 - 236
  • [8] Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?
    Hansson, Oskar
    Mormino, Elizabeth C.
    [J]. BRAIN, 2018, 141 : 1241 - 1244
  • [9] Advance of sporadic Alzheimer's disease animal models
    Zhang, Lili
    Chen, Chen
    Mak, Marvin S. H.
    Lu, Junfeng
    Wu, Zeqing
    Chen, Qiuhe
    Han, Yifan
    Li, Yuefeng
    Pi, Rongbiao
    [J]. MEDICINAL RESEARCH REVIEWS, 2020, 40 (01) : 431 - 458
  • [10] Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials
    Thomas, Ronald G.
    Albert, Marilyn
    Petersen, Ronald C.
    Aisen, Paul S.
    [J]. ALZHEIMERS & DEMENTIA, 2016, 12 (05) : 598 - 603